Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials

Author(s):
Moran, A.; Bundy, B.; Becker, D.J.; DiMeglio, L.A.; Gitelman, S.E.; Goland, R.; Greenbaum, C.J.; Herold, K.C.; Marks, J.B.; Raskin, P.; Sanda, S.; Schatz, D.; Wherrett, D.K.; Wilson, D.M.; Krischer, J.P.; Skyler, J.S.; Pickersgill, L.; Koning, E. de; Ziegler, A.G.; Boehm, B.; Badenhoop, K.; Schloot, N.; Bak, J.F.; Pozzilli, P.; Mauricio, D.; Donath, M.Y.; Castano, L.; Wagner, A.; Lervang, H.H.; Perrild, H.; Mandrup-Poulsen, T.; Type 1 Diabet TrialNet Canakinumab; AIDA Study Grp
Published
2013
Publication type
Article / Letter to editor
Date issued
2013-06-01
Language
English
Is part of
Lancet (2013), Vol. 381, no. 9881, p. 1905-1915
hdl
1887/100535
doi
10.1016/S0140-6736(13)60023-9